Boston Partners
AMAG

Boston Partners’s AMAG Pharmaceuticals AMAG Stock Holding History

Boston Partners’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-182,301
Closed -$6.34M – 805
2016
Q4 		$6.34M Hold
182,301
– – 0.01% 456
2016
Q3 		$4.47M Hold
182,301
– – 0.01% 511
2016
Q2 		$4.36M Hold
182,301
– – 0.01% 511
2016
Q1 		$4.27M Buy
182,301
+126,020
+224% +$2.99M 0.01% 494
2015
Q4 		$1.7M Buy
+56,281
New +$1.82M ﹤0.01% 632

Other funds holding AMAG

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Boston Partners's AMAG Position: Q1 2017 in Review

Boston Partners sold out of AMAG Pharmaceuticals (AMAG) in Q1 2017, closing a stake of 182,301 shares — an estimated $6.34M sold.

Boston Partners first reported a position in AMAG in Q4 2015 and held it in 5 quarters. The position peaked at $6.34M in Q4 2016. 185 funds tracked by Wall St. Rank hold AMAG as of Q1 2017.

  • Boston Partners reported no remaining AMAG Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Boston Partners sold 182,301 AMAG Pharmaceuticals shares in Q1 2017, an estimated $6.34M.
  • Boston Partners first reported a position in AMAG Pharmaceuticals in Q4 2015 and held it in 5 quarters.
  • Boston Partners's AMAG Pharmaceuticals position peaked at $6.34M in Q4 2016.
  • 185 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q1 2017.

Based on Boston Partners's 13F filing for Q1 2017, filed 3 May 2017.